Pioglitazone Prevents Hemorrhagic Infarction After Transient Focal Ischemia in Type 2 Diabetes
Autor: | Hidenori Oishi, Takao Urabe, Hajime Arai, Kenji Yatomi, Yumiko Mitome-Mishima, Nobukazu Miyamoto, Ryota Tanaka, Hiroshi Hasegawa, Nobutaka Hattori |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Ischemia Type 2 diabetes medicine.disease_cause Neuroprotection Brain Ischemia Mice Internal medicine medicine Animals Humans Adiponectin Pioglitazone business.industry General Neuroscience Infarction Middle Cerebral Artery General Medicine medicine.disease Diabetes Mellitus Type 2 Cardiology Metabolic syndrome business Reperfusion injury Oxidative stress medicine.drug |
Zdroj: | Neuroscience research. 170 |
ISSN: | 1872-8111 |
Popis: | Pioglitazone (PGZ), a PPARγ agonist, has been used for diabetic patients as an insulin-sensitizing agent. Recent studies have demonstrated that PGZ increases adiponectin (APN) levels and provides vascular protection in ischemic conditions. This study was designed to assess the neuroprotective effects of PGZ against cerebral ischemia-reperfusion injury via an APN-related mechanism. Type 2 diabetic leptin-deficient mice (db/db) were administered PGZ for 1 week, and plasma insulin and APN levels were measured. These mice received a middle cerebral artery occlusion and reperfusion injury, and they were evaluated for the infarct volume and by immunohistochemistry and western blotting analysis at several time points after ischemia. PGZ-administered db/db mice showed improved insulin sensitivity, and the hemorrhagic rate and infarct volume were decreased (P < 0.05). In the PGZ-administered group, plasma APN levels increased compared with the vehicle group. In the db/db group, PGZ administration significantly suppressed inflammatory reactions and oxidative stress after reperfusion (P < 0.05). PGZ may be applicable for acute cerebral ischemia treatment in metabolic syndrome patients as well as antidiabetic agents. |
Databáze: | OpenAIRE |
Externí odkaz: |